Renee N. Donahue, Ph.D.
Dr. Donahue is a Staff Scientist and Head of the Molecular Immunology Group in the Laboratory of Tumor Immunology and Biology, NCI. She received her Ph.D. in Cell and Molecular Biology from the Pennsylvania State University College of Medicine, and joined the NCI as a Postdoctoral Fellow in 2011. The Molecular Immunology Group investigates the immune response of patients enrolled in our clinical trials to identify patients, prior to or early following therapy, who go on to respond well to
various cancer immunotherapies.
1) cellular and molecular immunology, 2) tumor immunology, 3) cancer immunotherapy,
4) immune biomarkers
The Laboratory of Tumor Immunology and Biology develops novel immunotherapeutics that are translated from hypothesis-driven preclinical studies to clinical trials. The Molecular Immunology Group is working to characterize the immune response of patients enrolled in our clinical trials to identify patients, prior to or early following therapy, who go on to respond well to various cancer immunotherapies. Our research program develops innovative methods to assess the immune response of cancer patients treated with combination immunotherapies as well as so-called “non-immune”‒based therapies. We investigate specific immune cell subsets in the peripheral blood of patients to identify potential correlations with clinical responses. We also conduct preclinical and translational research in the areas of tumor immunology and immunotherapy, concentrating on mechanisms of tumor cell‒immune cell interactions and immune cell function, with a focus on combining cancer immunotherapies with novel targeted agents. These studies provide critical information toward the development of more effective immunotherapeutic approaches to cancer.
Selected Key Publications
A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules.Clin Cancer Res. 25: 4933-44, 2019. [ Journal Article ]
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma.J ImmunoTher Cancer. 7: 269, 2019. [ Journal Article ]
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.J Immunother Cancer. 5:20: 2017. [ Journal Article ]
- Cancer Immunol Res. 4: 755-65, 2016. [ Journal Article ]
Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients that are not detected in analysis of standard immune cell types.J. Circ Biomark. 5:5: [ Journal Article ]
Dr. Renee Donahue received her B.S. in Molecular Biology from Grove City College in 2004, and Ph.D. in Cell and Molecular Biology from the Pennsylvania State University College of Medicine in 2011. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2017. Dr. Donahue’s current research focuses on investigating the immune response of patients enrolled in our clinical trials, prior to, as well as following therapy, to identify immune signatures that correlate with clinical outcome.
|Nicole J. Flynn Ph.D.||Postdoctoral Fellow (CRTA)|
|Angela Schwab||Biologist (Contr)|
|Yo-Ting Tsai Ph.D.||Postdoctoral Fellow (Visiting)|
|Keanan Wright||Biologist (Contr.)|